Skip to search formSkip to main contentSkip to account menu

Anti-GCC Antibody-Drug Conjugate MLN0264

Known as: MLN0264 
An antibody-drug conjugate (ADC) containing a monoclonal antibody directed against guanylyl cyclase C (GCC or GUCY2C) conjugated to… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Guanylyl cyclase C (GCC) is a cell-surface protein that is expressed by normal intestinal epithelial cells, more than 95% of… 
2018
2018
  • Y. Bang, T. Takano, T. Doi
  • Cancer research and treatment : official journal…
  • 2018
  • Corpus ID: 4685156
Purpose This phase 1 dose-escalation portion of the study evaluated the safety, pharmacokinetics (PK), and antitumor activity of… 
2017
2017
SummaryBackground This phase II open-label, multicenter study evaluated the efficacy, safety, and tolerability of TAK-264 in… 
2017
2017
SummaryBackground The first-in-class antibody–drug conjugate TAK-264 (formerly MLN0264) consists of an antibody targeting… 
2016
2016
Purpose: To assess the safety, tolerability, and preliminary antitumor activity of the investigational anti–guanylyl cyclase C… 
2014
2014
3546 Background: This first-in-human study (NCT01577758) assessed the safety and tolerability, dose limiting toxicities (DLTs… 
2014
2014
MLN0264 is an investigational antibody-drug conjugate (ADC) that consists of the human anti-guanylyl cyclase C (GCC) antibody… 
2013
2013
TPS3646 Background: MLN0264, an investigational ADC that targets GCC, consists of a fully human monoclonal antibody conjugated to…